Biohaven’s treatment for Lou Gehrig’s disease fails to win FDA nod

By | July 20, 2019

FILE PHOTO: The logo for Biohaven Pharmaceutical Holding Company is displayed on a screen during the company’s IPO on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 4, 2017. REUTERS/Brendan McDermid

(Reuters) – Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease, sending its shares down nearly 6% in extended trading.

The company said the Food and Drug Administration issued a complete response letter, raising concerns related to an active pharmaceutical ingredient (API) used in a 2017 study that was made by Apotex Pharmachem India Pvt Ltd between 2014 and 2016.

Biohaven said that the API is now being sourced from another supplier, with which there are no chemistry, manufacturing, and control issues that have been identified.

Amyotrophic lateral sclerosis is a rare neurologic disease, which mainly affects the nerve cells responsible for controlling voluntary muscle movement such as walking or talking.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva

Reuters: Health News